Ben-Tzvi Avraham 4
4 · TITAN PHARMACEUTICALS INC · Filed Oct 8, 2025
Insider Transaction Report
Form 4
Ben-Tzvi Avraham
Director
Transactions
- Disposition to Issuer
Common Stock
2025-10-01−3,313→ 0 total - Disposition to Issuer
Option to Purchase Common Stock
2025-10-01−1,250→ 0 total→ Common Stock (1,250 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2025-10-01−5,000→ 0 total→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").
- [F2]Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
- [F3]Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.